Kelly?Anne Phillips|Karin Ribi|Zhuoxin Sun|Alisa Stephens|Alastair M. Thompson|Vernon Harvey|Beat Thürlimann|Fátima Cardoso|Olivia Pagani|Alan S. Coates|Aron Goldhirsch|Karen N. Price|Richard D. Gelber|Jürg Bernhard
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
Peter MacCallum Cancer Centre|University of Melbourne
cognitive function postmenopausal women receiving letrozole tamoxifen adjuvant endocrine treatment compared fifth year treatment substudy big 198 trial big 198 patients randomized receive adjuvant 5years tamoxifen b 5years letrozole c 2years tamoxifen followed 3years letrozole 2years letrozole followed 3years tamoxifen primary comparison difference composite score patients taking letrozole bc n65 vs tamoxifen ad n55 patients taking letrozole better overall cognitive function taking tamoxifen difference mean composite zscores028 p004 95 ci 002 054 cohens d040 indicating small moderate effect substudy breast cancer patients taking adjuvant letrozole fifth year treatment better cognitive function taking tamoxifen suggesting aromatase inhibitors adversely impact cognition compared tamoxifen